16.12.2012 Views

Front Matter (PDF) - Investigative Ophthalmology & Visual Science

Front Matter (PDF) - Investigative Ophthalmology & Visual Science

Front Matter (PDF) - Investigative Ophthalmology & Visual Science

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

McCarey et al.<br />

Polack and Sugar<br />

Albert et al.<br />

Kreuger et al<br />

Binder et al.<br />

Green et al.<br />

Jampol etal.<br />

Katz et al.<br />

Malik et al.<br />

Levy<br />

Wickham and Worthen<br />

van Alphen<br />

Chen and Chylack<br />

Kurzel and Heinrikson<br />

JUNE 1976 Vol. 15/6<br />

A journal of Clinical and Basic Research<br />

Official Publication of the Association for<br />

Research in Vision and <strong>Ophthalmology</strong><br />

Phacoemulsification, 449<br />

Phacoemulsification, 458<br />

Herpes hominis keratitis therapy, 470<br />

Lacrimal gland sialic acid, 479<br />

Oxytocic antibodies, 481<br />

Stromal sodium binding, 484<br />

Nitrogen mustard, 486<br />

Timolol ophthalmic solution, 489<br />

Isoproterenol and norepinephrine, 492<br />

Axoplasmic transport, 495<br />

Pericanalicular region, 499<br />

Intraocular adrenergic receptors, 502<br />

Lens phosphofructokinase, 505<br />

Ocular bilirubin, 509<br />

The C.V. Mosby Company<br />

INOPAO 15 (6) 443-512 (1976) A


Severe ocular inflammation<br />

calls for potent therapy...<br />

The basis for a rational choice between<br />

FML® (fluorometholone) and Pred Forte® (prednisolone acetate) 1%<br />

When to use a potent steroid. If not treated<br />

promptly and effectively, ocular inflammation is<br />

at best painful and unsightly. At worst, it's<br />

potentially damaging to the patient's vision. The<br />

more severe the inflammatory condition, the<br />

greater the need for therapeutic potency. For<br />

example, FML and Pred Forte provide the high<br />

level of anti-inflammatory activity needed to<br />

effectively treat even the most severe steroid<br />

responsive inflammation of the palpebral and<br />

bulbar conjunctiva, cornea and anterior segment<br />

of the globe.<br />

The basic rationale behind the use of potent<br />

ophthalmic steroids such as FML and Pred<br />

Forte is to maintain functional integrity of the<br />

eye. In general, as long as evidence of active<br />

inflammation persists, it may be hazardous to<br />

discontinue steroid therapy. Use of potent<br />

steroids may in fact help preserve the ocular<br />

structure. 1<br />

When not to use potent steroids. Despite<br />

their usefulness, there are times when potent<br />

steroids (and mild ones too, for that matter)<br />

should be used with extreme caution-or not at<br />

all. It is generally agreed that untreated purulent<br />

infections, most viral diseases and ocular<br />

fungal infestations should be considered as<br />

contraindications to the use of these agents.<br />

Indications and methods of use. Either FML<br />

or Pred Forte may be used to treat moderately<br />

severe to severe steroid responsive inflammatory<br />

conditions such as iritis, uveitis, iridocyclitis,<br />

episcleritis and resistant ocular allergy. In addition,<br />

data 2 made available recently attest to the<br />

usefulness of FML in long-term treatment of<br />

inflammation following cataract removal and<br />

keratoplasty. The patient photos to the right<br />

demonstrate the effectiveness of both FML and<br />

Pred Forte in severe ocular inflammation.<br />

The usual method of administering either FML<br />

or Pred Forte is to instill one or two drops into<br />

the conjunctival sac two to four times a day.<br />

But to provide maximum therapeutic effectiveness<br />

when the severity of the inflammation dictates,<br />

the dosage can be safely increased to two<br />

drops every hour during the first 24 to 48 hours.<br />

Seminais<br />

l~ IVIL_ (fluorometholone) 0.1% Liquifilm® Sterile Ophthalmic Suspension<br />

ACTIONS Inhibition of the inflammatory response to inciting<br />

agents of mechanical, chemical or immunological nature. No<br />

generally accepted explanation of this steroid property has<br />

been advanced. Adrenocorticosteroids and their derivatives<br />

are capable of producing a rise in intraocular pressure. In<br />

clinical studies on patients' eyes treated with both dexamethasone<br />

and fluorometholone, fluorometholone demonstrated<br />

a lower propensity to increase intraocular pressure than did<br />

dexamethasone. INDICATIONS For steroid responsive inflammation<br />

of the palpebral and bulbar conjunctiva, cornea and<br />

anterior segment of the globe. CONTRAINDICATIONS Acute<br />

superficial herpes simplex keratitis. Fungal diseases of ocular<br />

structures. Vaccinia, varicella and most other viral diseases of<br />

the cornea and conjunctiva. Tuberculosis of the eye. Hypersensitivity<br />

to the constituents of this medication. WARNINGS<br />

Steroid medication in the treatment of herpes simplex keratitis<br />

(involving the stroma) requires great caution; frequent slitlamp<br />

microscopy is mandatory. Prolonged use may result in<br />

glaucoma, damage to the optic nerve, defects in visual acuity<br />

and fields of vision, posterior subcapsuiar cataract formation,<br />

or may aid in the establishment of secondary ocular infections<br />

from fungi or viruses liberated from ocular tissue. In those<br />

diseases causing thinning of the cornea or solera, perforation<br />

has been known to occur with use of topical steroids. Acute<br />

purulent untreated infection of the eye may be masked or<br />

activity enhanced by presence of steroid medication. Safety<br />

and effectiveness have not been demonstrated in children of<br />

the age group 2 years or below. Use In Pregnancy: Safety of<br />

the use of topical steroids during pregnancy has not been<br />

established. PRECAUTIONS As fungal infections of the cornea<br />

are particularly prone to develop coincidentally with long-term<br />

local steroid applications, fungus invasion must be suspected<br />

in any persistent corneal ulceration where a steroid has been<br />

used or is in use. Intraocular pressure should be checked<br />

frequently. ADVERSE REACTIONS Glaucoma with optic nerve<br />

damage, visual acuity or field defects, posterior subcapsular<br />

cataract formation, secondary ocular infection from pathogens<br />

liberated from ocular tissues, perforation of the globe. DOSAGE<br />

AND ADMINISTRATION 1 to 2 drops instilled into the conjunctival<br />

sac two to four times daily. During the initial 24 to 48 hours<br />

the dosage may be safely increased to 2 drops every hour.<br />

Care should be taken not to discontinue therapy prematurely.


FME<br />

PredFbrte<br />

(fluorometholone) (prednisolone acetate) 1%<br />

FML vs Pred Forte: A choice. Both FML and Pred Forte work. FML has been shown to have<br />

less propensity than dexamethasone to raise IOR And recent animal data 3 indicate that Pred Forte<br />

exhibits maximal corneal penetration, through intact epithelium, compared to commonly used<br />

steroid phosphate and alcohol derivatives. So when potent anti-inflammatory activity is required<br />

and your clinical judgement anticipates something beyond short-term therapy, FML appears to be<br />

the drug of choice. But for severe disorders where safety is less of a concern, Pred Forte<br />

provides a potent alternative to FML.<br />

Potency you can see<br />

y<br />

Patient CH. White male. Age 46. Acute episcleritis secondary<br />

to rheumatoid arthritis. Treatment started 2/24: FML one<br />

drop every hour for 48 hours then one drop every two hours<br />

for 36 hours then one drop every four hours thereafter<br />

r<br />

Patient CH on 3/9. FML therapy stopped.<br />

References<br />

1. Leopold, I.H. The steroid shield in ophthalmology, Trans<br />

Amer Acad Ophth & Oto 71:273-289, 1967,<br />

2. Castroviejo, R. Data presented at 79th American<br />

Academy of <strong>Ophthalmology</strong> and Ototaryngology, Dallas,<br />

Oct. 1974.<br />

Patient LV. White male. Age 57. Acute episcleritis. Treatment<br />

started 2/27: Pred Forte one drop every hour for 48 hours<br />

then one drop every two hours for 36 hours then one drop<br />

every four hours thereafter; warm compresses and<br />

scopolamine ointment twice daily.<br />

Patient LV on 3/12. Pred Forte therapy stopped.<br />

3. Leibowitz, Howard M., Data presented at 79th American<br />

Academy of <strong>Ophthalmology</strong> and Ototaryngology, Dallas,<br />

Oct. 1974.<br />

Photos by Dr. Ira Abrahamson, Cincinnati, Ohio<br />

Pred Forte' (prednisolone acetate) 1% Sterile Ophthalmic Suspension<br />

INDICATIONS For steroid responsive inflammation of the<br />

palpebral and bulbar conjunctiva, cornea and anterior segment<br />

of the globe. CONTRAINDICATIONS Acute untreated purulent<br />

ocular infections, acute superficial herpes simplex (dendritic<br />

keratitis), vaccinia, varicella and most other viral diseases of<br />

the cornea and conjunctiva, ocular tuberculosis, and fungal<br />

diseases of the eye, and sensitivity to any components of the<br />

formulation. WARNINGS 1. In those diseases causing thinning<br />

of the cornea, perforation has been reported with the use of<br />

topical steroids. 2. Since PRED FORTE® contains no antimicrobial,<br />

if infection is present appropriate measures must be taken<br />

to counteract the organisms involved. 3. Acute purulent infections<br />

of the eye may be masked or enhanced by the use of<br />

topical steroids. 4. Use of steroid medication in the presence<br />

of stromal herpes simplex requires caution and should be<br />

followed by frequent mandatory slit-lamp microscopy. 5. As<br />

fungal infections of the cornea have been reported coincidentally<br />

with long-term local steroid applications, fungal invasion<br />

may be suspected in any persistent corneal ulceration<br />

where a steroid has been used, or is in use. 6. Use of topical<br />

corticosteroids may cause increased intraocular pressure in<br />

certain individuals.This may result in damage to the optic nerve<br />

with defects in the visual fields. It is advisable that the intraocular<br />

pressure be checked frequently. 7. Use in Pregnancy-<br />

Safety of intensive or protracted use of topical steroids during<br />

pregnancy has not been substantiated. PRECAUTIONS Posterior<br />

subcapsular cataract formation has been reported after<br />

heavy or protracted use of topical ophthalmic corticosteroids.<br />

Patients with histories of herpes simplex keratitis should be<br />

treated with caution. ADVERSE REACTIONS Increased intraocular<br />

pressure, with optic nerve damage, defects in the visual<br />

fields. Also posterior subcapsular cataract formation, secondary<br />

ocular infections from fungi or viruses liberated from<br />

ocular tissues, and perforation of the globe when used in conditions<br />

where there is thinning of the cornea o r sclera. Systemic<br />

side effects may occur with extensive use of steroids. DOSAGE<br />

AND ADMINISTRATION 1 to 2 drops instilled into the conjunctival<br />

sac two to four times daily. During the initial 24 to 48 hours<br />

the dosage may be safely increased to 2 drops every hour.<br />

Care should be taken not to discontinue therapy prematurely.<br />

Irvine Califaria/PohteClaire,P.Q.,Canada


Novascan: the User's SEM<br />

Zeiss introduces Novascan, an SEM with 100A edge resolution<br />

guaranteed, magnification from 5X to 150.000X,<br />

and accelerating voltages of 1-5, 15, and 30kV. Like all<br />

Zeiss electron microscopes, its design reflects first and<br />

foremost the needs of the user:<br />

The most accessible<br />

chamber<br />

Novascan is the only SEM with true access to the chamber<br />

from above. It opens automatically at the touch of a<br />

button, accepts the largest of samples, lets you optimize the<br />

positions of specimen and detectors with ease. Since it has<br />

more ports than any other SEM, you can permanently attach<br />

additional detectors or accessories, e.g. an X-ray analyzer of<br />

your choice. And the large 5-axis goniometer stage is permanently<br />

mounted for utmost stability.<br />

The finest TV image<br />

You won't believe the quality of the TV image until you<br />

see it. Use it at high magnifications for critical focusing, at<br />

low magnifications for specimen orientation. Then switch for<br />

recording to the high-resolution CRT that's combined with the<br />

built-in push-button controlled camera.<br />

The most attractive price<br />

For under $40,000, you get features you'd never expect.<br />

Besides the secondary electron mode, standard are also the<br />

back-scattered and cathodoluminescence electron modes—as<br />

are signal inversion, reduced raster, 90° scan rotation, X-Y<br />

±20 micron scan shift, and gamma contrast enhancement.<br />

There is also a full line of accessories for special applications.<br />

For complete details, write or call today.<br />

Nationwide service<br />

Carl Zeiss, Inc., 444 5th Avenue, N.Y., N.Y. 10018 (212) 730-4400. Branches in: Atlanta, Boston, Chicago, Columbus, Houston,<br />

Los Angeles. San Francisco. Washington. D.C. In Canada: 45 Vallevbrook Drive. Don Mills. Ont.. M3B 2S6. Or call (416) 449-4660.


Page 4<br />

[ Ophttialmid<br />

Ointment \<br />

SODIUM i<br />

CHLORIDE!<br />

5% I<br />

iflill<br />

Muro<br />

Ointment<br />

Sodium Chloride<br />

MURO OINTMENT NO. 128 / SUPPLIED 1/8 02.<br />

An ointment of hypertonic sodium chloride solution in a<br />

base of lanolin, liquid petrolatum and white petrolatum.<br />

Apply to conjuctiva at bedtime.<br />

TO REDUCE CORNEAL EDEMA<br />

Murocoll Methylcellulose<br />

4000 cps 0.9%<br />

with Sodium Chloride 5%<br />

MUROCOLL PRODUCT NO. 4 / SUPPLIED 15cc and 30cc<br />

A hypertonic solution of sodium chloride with methylcellulose.<br />

Preservatives - methylparaben and propylparaben.<br />

TO REDUCE CORNEAL EDEMA: 1 or 2 drops in affected<br />

eye 3 times a day or as directed by the physician.<br />

MURO preparations are available to all pharmacies and<br />

hospitals through their drug wholesaler.<br />

Complete ophthalmologic formulary available on request.<br />

Federal law prohibits dispensing without prescription.<br />

MURO PHARMACAL LABORATORIES, INC.<br />

121 Liberty Street • Quincy, Mass. 02169<br />

Area Code 617 • 479 2680


The new<br />

generation of<br />

disposable<br />

cryoextractors<br />

Reliability is the keynote of the all new 2001.<br />

Eight proven design changes project the<br />

2001 into a totally new product generation.<br />

The 2OOFs unique 10 second delayed<br />

response feature allows you to go on warm for<br />

maximal adherence and ice ball formation. It is<br />

the only simple disposable with this singular<br />

advantage of warm or cold contact. With a running<br />

time in excess of two minutes you have<br />

ample margin time to compensate for any minor<br />

interruptions.<br />

The 2001 has the advantage of being a<br />

fine surgical instrument rather than just a gas •!<br />

container with a spout or delivery tube.<br />

Of CONNECTICUT INCORPORATED<br />

77O RIVER ROAD. SHELTON. CT O6484 2O3/?29-6321


Topcon Advances Projection Perimetry<br />

Another Important Step.<br />

The SBP-11 is recognized for its<br />

accuracy and ease of operation in<br />

critical perimetry field testing because<br />

of our constant monitoring for improvements<br />

made possible through new<br />

technological developments.<br />

One such improved feature on the<br />

SBP-11 is a new device for occluding<br />

the target. Its smoothness and silence<br />

enables the operator to achieve optimum<br />

accuracy of measurements.<br />

TOPCON SBP-11<br />

1<br />

Other significant advantages of the<br />

SBP-11 include:<br />

• Reproducible environmental conditions<br />

for accuracy in subsequent<br />

examinations.<br />

• Constant monitoring of patient's<br />

fixation with sighting telescope.<br />

• Automatic recording probe with manual<br />

override (standard equipment.)<br />

These features combined with a reasonable price and IMMEDIATE<br />

AVAILABILITY should make the Topcon SBP-11 your first choice for keeping<br />

in step with today's sophisticated diagnostic techniques. Contact your<br />

Topcon distributor or write us for details.<br />

TOPCON<br />

A New V\forld of Precision Optics<br />

Topcon Instrument Corp. of America, 9 Keystone Place, Paramus, New Jersey 07652


For uninterrupted control of I.O.R<br />

...never more than one or two instillations<br />

Page 10<br />

Scanning electron microscopy of<br />

primate trobecular meshwork (XOOO):<br />

Viewed here is Schlemm's canal<br />

along with uveal and corneoscleral<br />

meshwork. (Photo courtesy<br />

Douglas R. Anderson, M.D.]<br />

This area is the site of the prime<br />

pathologic changes which are<br />

responsible for glaucoma and the<br />

focus of most of the medical<br />

procedures for treatment of the disease.


Because PHOSPHOLINE IODIDE is long-acting, it can help provide<br />

uninterrupted control of intraocular pressure in chronic simple [open-angle)<br />

glaucoma or glaucoma secondary to aphakia. Just one or, at most,<br />

two instillations of PHOSPHOLINE IODIDE (one at bedtime, and, if necessary,<br />

one in the morning) are generally needed.<br />

Although PHOSPHOLINE IODIDE is longer-acting than other miotics,<br />

it is not more potent. With four concentrations available, it offers a high degree of<br />

dosage flexibility for uninterrupted control of intraocular pressure... used alone<br />

or in combination with other medication.<br />

When starting PHOSPHOLINE IODIDE therapy 0.03%-the lowest strength -<br />

is the logical choice. If strengths of 0.06%, 0.125%, or 0.25% are required,<br />

the initial use of the 0.03% will be helpful in smoothing the transition.<br />

PHOSPHOLINE IODIDE' BE5K3&<br />

(echothiophate iodide for ophthalmic solution)<br />

See next page of advertisement lor prescribing information<br />

Page 11


PHOSPHOLINE IODIDE<br />

®<br />

(echothiophate iodide)<br />

in the management of<br />

chronic simple (open-angle)<br />

glaucoma or glaucoma<br />

secondary to aphakia<br />

BRIEF SUMMARY<br />

(For full prescribing information, see package circular]<br />

PHOSPHOLINE IODIDE"<br />

(ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION)<br />

PHOSPHOLINE IODIDE is a long-acting cholinesterase inhibitor<br />

for topical use.<br />

Indications: Glaucoma-Chronic open-angle glaucoma. Subacute<br />

or chronic angle-closure glaucoma after iridectomy or<br />

where surgery is refused or contraindicated. Certain non-uveitic<br />

secondary types of glaucoma, especially glaucoma following<br />

cataract surgery.<br />

Accommodative esotropia-Concomitant esotropias with a<br />

significant accommodative component.<br />

Contraindications: 1. Active uveal inflammation.<br />

2. Most cases of angle-closure glaucoma, due to the possibility<br />

of increasing angle block.<br />

3. Hypersensitiyity to the active or inactive ingredients.<br />

Warnings: 1. Use in Pregnancy: Safe use of anticholinesterase<br />

medications during pregnancy has not been established, nor<br />

has the absence of adverse effects on the fetus or on the<br />

respiration of the neonate.<br />

2. Succinylcholine should be administered only with great<br />

caution, if at all, prior to or during general anesthesia to patients<br />

receiving anticholinesterase medication because of possible<br />

respiratory or cardiovascular collapse.<br />

3. Caution should be observed in treating glaucoma with<br />

PHOSPHOLINE IODIDE in patients who are at the same time<br />

undergoing treatment with systemic anticholinesterase medications<br />

for myasthenia gravis, because of possible adverse<br />

additive effects.<br />

Precautions: 1. Gonioscopy is recommended prior to initiation<br />

of therapy.-<br />

2. Where there is a quiescent uveitis or a history of this condition,<br />

anticholinesterase therapy should be avoided or used<br />

cautiously because of the intense and persistent miosis and<br />

ciliary muscle contraction that may occur.<br />

3. While systemic effects are infrequent, proper use of the<br />

drug requires digital compression of the nasolacrimal ducts for<br />

a minute or two following instillation to minimize drainage into<br />

the nasal chamber with its extensive absorption area. The hands<br />

should be washed immediately following instillation.<br />

4. Temporary discontinuance of medication is necessary if<br />

salivation, urinary incontinence, diarrhea, profuse sweating,<br />

muscle weakness, respiratory difficulties, or cardiac irregularities<br />

occur.<br />

5. Patients receiving PHOSPHOLINE IODIDE who are exposed<br />

to carbamate or organophosphate type insecticides and<br />

pesticides (professional gardeners, farmers, workers in plants<br />

manufacturing or formulating such products, etc.) should be<br />

Page 12<br />

warned of the additive systemic effects possible from absorption<br />

of the pesticide through the respiratory tract or skin. During<br />

periods of exposure to such pesticides, the wearing of respiratory<br />

masks, and frequent washing and clothing changes<br />

may be advisable.<br />

6. Antichqlinesterase drugs should be used with extreme caution,<br />

if at all, in patients with marked vagotonia, bronchial<br />

asthma, spastic gastrointestinal disturbances, peptic ulcer, pronounced<br />

bradycardia and hypotension, recent myocardial infarction,<br />

epilepsy, parkinsonism, and other disorders that may<br />

respond adversely to vagotonic effects.<br />

7. Anticholinesterase drugs should be employed prior to<br />

ophthalmic surgery only as a considered risk because of the<br />

possible occurrence of hyphema.<br />

8. PHOSPHOLINE IODIDE (echothiophate iodide) should be<br />

used with great caution, if at all, where there is a prior history of<br />

retinal detachment.<br />

Adverse Reactions: 1. Although the relationship, if any, of retinal<br />

detachment to the administration of PHOSPHOLINE IODIDE<br />

has not been established, retinal detachment has been reported<br />

in a few cases during the use of PHOSPHOLINE IODIDE in<br />

adult patients without a previous history of this disorder.<br />

2. Stinging, burning, lacrimation, lid muscle twitching, conjunctival<br />

and ciliary redness, browache, induced myopia with<br />

visual blurring may occur.<br />

3. Activation of latent iritis or uveitis may occur.<br />

4. Iris cysts may form, and if treatment is continued, may<br />

enlarge and obscure vision. This occurrence is more frequent<br />

in children. The cysts usually shrink upon discontinuance of<br />

the medication, reduction in strength of the drops or frequency<br />

of instillation. Rarely, they may rupture or break free into the<br />

aqueous. Regular examinations are advisable when the drug is<br />

being prescribed for the treatment of accommodative esotropia.<br />

5. Prolonged use may cause conjunctival thickening, obstruction<br />

of nasolacrimal canals.<br />

6. Lens opacities occurring in patients under anticholinesterase<br />

therapy have been reported; routine examinations should<br />

accompany prolonged use.<br />

7. Paradoxical increase in intraocular pressure may follow<br />

anticholinesterase instillation. This may be alleviated by prescribing<br />

a sympathomimetic mydriatic such as phenylephrine.<br />

Overdosage: Antidotes are atropine, 2 mg parenterally;<br />

PROTOPAM" CHLORIDE (pralidoxime chloride), 25 mg per kg<br />

intravenously; artificial respiration should be given if necessary.<br />

How Supplied: Four potencies are available. 1.5 mg package<br />

for dispensing 0.03% solution; 3.0 mg package for 0.06% solution;<br />

6.25 mg package for 0.125% solution; 12.5 mg package<br />

for 0.25% solution. Also contains potassium acetate (sodium<br />

hydroxide or acetic acid may have been incorporated to adjust<br />

pH during manufacturing), chlorobutanol (chloral derivative),<br />

mannitol, boric acid and exsiccated sodium phosphate.<br />

7630<br />

The Ophthalmos Division<br />

AYERST LABORATORIES<br />

New York, N.Y. 10017


investigative ophthalmology<br />

A Journal of Clinical and Basic Research<br />

Official Publication of the Association for Research in Vision and <strong>Ophthalmology</strong><br />

EDITOR<br />

Herbert E. Kaufman, M.D.<br />

Professor of <strong>Ophthalmology</strong> and Pharmacology<br />

College of Medicine, University of Florida<br />

Gainesville, Florida 32610<br />

Manuscripts<br />

Address correspondence related to manuscripts<br />

to the Editor, Herbert E. Kaufman, M.D., Department<br />

of <strong>Ophthalmology</strong>, College of Medicine,<br />

University of Florida, Gainesville, Florida 32601.<br />

Scope and selection. <strong>Investigative</strong> <strong>Ophthalmology</strong><br />

is intended to convey information to those interested<br />

in all areas of vision research. We welcome<br />

the submission of manuscripts describing<br />

laboratory and clinical investigations of the eye<br />

and the visual processes. Papers submitted for<br />

publication should be original and should not be<br />

submitted for publication elsewhere. Papers submitted<br />

by non-members of the Association for<br />

Research in Vision and <strong>Ophthalmology</strong> will be<br />

given equal consideration. Papers should be<br />

written in English and contributed solely to<br />

<strong>Investigative</strong> <strong>Ophthalmology</strong>. Preference will be<br />

given to timely reports, to manuscripts of 2,000<br />

words or less (approximately eight double-spaced<br />

typewritten pages), and to reports of broadest<br />

general interest.<br />

Statements and opinions expressed in the articles<br />

and communications herein are those of the<br />

author(s) and not necessarily those of the Editors)<br />

or publisher and the Editor(s) and publisher<br />

disclaim any responsibility or liability for<br />

such material. Neither the Editor(s) nor the<br />

publisher guarantee, warrant, or endorse any<br />

product or service advertised in this publication,<br />

nor do they guarantee any claim made by the<br />

manufacturer of such product or service.<br />

Style and organization. Articles should be written<br />

so as to be easily understandable to vision researchers<br />

in many fields. Abstracts should be as<br />

free of jargon and specialized language as possible<br />

and should specifically state the conclusions of the<br />

study. All investigators should specify any direct<br />

or indirect financial interest involved in the outcome<br />

of any paper or study, and all sources of<br />

support.<br />

Submit the original and three (3) copies of<br />

the manuscript and illustrations. Type manuscript<br />

double-spaced on one side of the paper. The<br />

following organization is recommended: 1. Abstract<br />

(250 words or less orienting the problem,<br />

describing the major observations, and stating the<br />

principal conclusion). 2. Introduction and objective<br />

of study (omit extensive reviews of the<br />

literature). 3. Methods and experimental design<br />

(brief but compatible with repetition of the work;<br />

refer to published procedures by reference only).<br />

Editorial communications<br />

PUBLISHER<br />

The C. V. Mosby Company<br />

11830 Westline Industrial Drive<br />

St. Louis, Missouri 63141, U. S. A.<br />

4. Results (describe with minimum of discussion<br />

—use such tables, photographs, and charts as<br />

are necessary to clarify and document the text).<br />

5. Discussion (limit to the data presented, their<br />

significance, and their limitations; avoid unsupported<br />

hypotheses). Avoid unusual abbreviations;<br />

employ standard chemical or nonproprietary pharmaceutical<br />

nomenclature. (See Style Manual for<br />

Biological Journals, 1960, American Institute of<br />

Biological <strong>Science</strong>s, 2000 P Street, N.W., Washington,<br />

D. C. 20036.)<br />

Key words. A list of 5 to 10 key words should<br />

be provided on a separate sheet. A selection will<br />

be made from these and printed at the head<br />

of the article to facilitate indexing and retrieval<br />

for the medical literature.<br />

References. Restrict the bibliography to pertinent<br />

references. Refer to them in the text by number<br />

only, and list and number them at the end of<br />

the manuscript in the order of their mention,<br />

using style found in the Cumulated Index, Medicus<br />

and in the following order: 1. Journal references:<br />

authors, title, journal, volume, page, and<br />

year. 2. Book references: authors, title, edition,<br />

city, year, and publisher. It is the author's responsibility<br />

to verify each reference.<br />

Illustrations. Results may be presented in tables<br />

or figures, but only under exceptional circumstances<br />

should the same data be presented in<br />

both. Illustrations should be numbered consecutively<br />

in Arabic, and marked lightly on the<br />

back with figure number, author's name, and<br />

"top." Type legends on a separate sheet. Provide<br />

unmounted, glossy photographic prints in which<br />

the details are clearly evident, or original illustrations<br />

on good quality paper on which the lining<br />

and lettering are done with India ink. Approximately<br />

three full pages of halftone illustrations,<br />

or their equivalent, are permitted without extra<br />

charge. Illustrations in excess of this amount will<br />

be billed to the author at approximately $25.00<br />

per full page. Authors who wish their electron<br />

micrographs to be printed on special paper will<br />

be billed at $52.00 per page. Arrangements should<br />

be made with the Editor for the use of color<br />

plates.<br />

Reports. Special consideration for rapid review and<br />

prompt publication will be given to Reports. These<br />

should be written in the same format as regular<br />

papers, including an abstract, but should be no<br />

longer than 5 double-spaced, typewritten pages<br />

in length, and may include up to 4 figures or<br />

tables.<br />

June 1976 Page 13


FIRST<br />

PREFILLED<br />

DISPOSABI<br />

^SYRINGE FO<br />

FLUORESC<br />

ANGIO<br />

Fluorescite' Irije 1<br />

(Fluorescein Sodium Injec<br />

(Syringe contains 5 ml of Fluorescite® Injection 10% With<br />

a 10 rnl capacity to facilitate aspiration) ^<br />

Modern angiography and<br />

ophthalmoscopy techniques<br />

are now made more<br />

convenient with ALCON's<br />

new prefilled, ready-to-use<br />

Fluorescite® Syringe.<br />

Completely disposable, it<br />

prevents spillage, assures<br />

fluorescein sterility and<br />

eliminates the possibility<br />

of foreign matter<br />

contamination.<br />

From ...of course.<br />

Alcon Laboratories, Inc., Fort Worth, Texas 76101<br />

10%<br />

\<br />

FLUORESCITE" INJECTION<br />

(Fluorescein Sodium Injection)<br />

Sterile Aqueous Solution<br />

DESCRIPTION: Syringe: A sterile<br />

aqueous solution of Fluorescein<br />

Sodium (equivalent to Fluorescein<br />

10%)withSodium Hydroxide and/or<br />

Hydrochloric Acid (to adjust pH),<br />

and Water for Injection. Ampul:<br />

A sterile aqueous solution of<br />

Fluorescein Sodium (equivalent lo<br />

Fluorescein 5% or 10%) with Sodium<br />

Bicarbonate (2.03% in 5%, 4.06%<br />

in 10%), Sodium Hydroxide (to<br />

adjust pH). Water for Injection.<br />

CONTRAINDICATIONS: Hypersensitivity<br />

to any component. PRE-<br />

CAUTIONS: Use with caution in<br />

patients with a history of hypersensitivity,<br />

allergies, asthma, etc.<br />

ADVERSE REACTIONS: Nausea,<br />

headache, gastrointestinal distress,<br />

urticaria and other symptoms of<br />

hypersensitivity, cardiac arrest,<br />

basilar artery ischemia, thrombophlebitis<br />

at injected site, and severe<br />

shock have occurred. DOSAGE:<br />

Inject contents of syringe or ampul<br />

rapidly into antecubital vein. An<br />

antihistamine and an ampul of 0.1%<br />

epinephrine for intravenous or intramuscular<br />

emergency use should<br />

always be available. HOW SUP-<br />

PLIED: 10% in 10 ml disposable<br />

syringe (5 ml fill) and 5 ml ampul.<br />

5% in 10 ml ampul.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!